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StevenseJohnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are both rare but serious idio-
syncratic drug reactions characterized by diffuse muco-epidermoid injury and high mortality. Kerati-
nocytes in both skin and mucous membranes (including eyes, mouth and genitalia) are injured resulting
in a diffuse maculopapular rash, blistering lesions and epithelial detachment with minimal force
(Nikolsky's sign). SJS is typically diagnosed when less than 10% of the skin surface is involved and the
term TEN is used in cases with more than 30% involvement. Respiratory involvement in SJS-TEN is
common with 30e50% of cases demonstrating respiratory epithelial sloughing with severe short and
long term complications. Patients who survive SJS-TEN are often left with impaired respiratory function
and bronchiolitis obliterans. Cases of bronchiolitis obliterans with SJS/TEN have been very rarely re-
ported. We report a case of phenytoin induced SJS/TEN followed by severe bronchiolitis obliterans in an
adult patient. The presentation, pathophysiology and management of SJS/TEN related bronchiolitis
obliterans is also reviewed.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case
A 67 year old nonsmoking Caucasian male was evaluated for
hypertension and a history of partial seizures. He had no prior
history of chronic obstructive pulmonary disease or asthma. His
family history was positive for GTP cyclohydrolase 1 gene mutation
in his sister and niece, which is an autosomal dominant condition
with childhood-onset dystonia.
In 2003, he was started on phenytoin for his partial seizures. He
had previously had an anaphylactic reaction to carbamazepine.
Three weeks after starting phenytoin, he broke out in a generalized
body rash involving both skin and mucous membranes. A diagnosis
of SteveneJohnson syndrome (SJS) was made and patient was
hospitalized for a week. During the hospitalization he developed
pneumonia and a staphylococcal skin infection for which he was
treated with antibiotics. His valproic acid dose needed to be
reduced due to a mild increase in liver enzymes and development
of a tremor.
Soon after hospital discharge, he noticed signiﬁcant shortness ofCritical Care Medicine, Mayo
Ltd. This is an open access article ubreath and inability to perform even basic activities of daily living.
He did not have any other symptoms of respiratory disease such as
cough, fever, hemoptysis or subsequent respiratory infections. His
dyspnea failed to improve over time and he remained markedly
impaired in his overall functioning. Chest radiographs done over
the years showed bilateral apical scarring with ﬁbrosis and volume
loss in upper lung ﬁelds (Fig. 1). Pulmonary function testing per-
formed in 2014 (11 years after the episode of SJS) showed very
severe obstruction with marked air trapping. His FEV1 was 1.02 L
(25% predicted), FVC was 2.80 L (52% predicted) and TLC (total lung
capacity) was 7.80 L (103% predicted). His residual volume was
markedly elevated at 4.88 L (222% predicted) with a RV/TLC ratio of
62.5%. No bronchodilator response was noted. His diffusing ca-
pacity was surprisingly normal (77% predicted) conﬁrming an
airway-centric obstructive process rather than a defect in pulmo-
nary gas-exchange. His resting and exercise oxygen concentrations
were also within normal limits. He was prescribed an albuterol
inhaler but was non-compliant. A chest CT scan showed ﬁndings
compatible with a diffuse airway centric-process affecting the large
and small airways (Fig. 2). The chest CT scan showed marked air
trapping with areas of mosaic attenuation along with diffuse
thickening of visible airway walls. In addition, there were areas of
peri-bronchial linear scarring noted in the upper lung ﬁelds andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest X-ray.
Fig. 2. Chest CT scan.
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the lack of other plausible explanations, all these ﬁndings werecompatible with a diagnosis of constrictive bronchiolitis/bron-
chiolitis obliterans secondary to the episode of SJS-TEN that had
occurred 11 years earlier. Repeat pulmonary function testing ob-
tained 1 year later in 2015 showed stable lung function.
2. Discussion
Both Stevens e Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are typically medication induced and are charac-
terized by widespread epidermal necrosis and mucous membrane
involvement. Mortality rates are generally below 5% for SJS but
approaches 30e50% or higher in patients with TEN with higher
mortality rates seen in older patients [1]. The cardinal manifesta-
tion of SJS-TEN is a febrile illness along with headache, cough,
malaise, rhinorrhea occurring along with prodromal ‘target’ type
skin lesions that later develop into a diffuse erythematous rash
involving both skin and mucous membranes [2]. As the disease
evolves, the epidermis undergoes necrosis in broad sheets and
classically detaches from the underlying dermis with even minimal
effort (Nikolsky sign). Mucous membrane involvement is reported
to occur in 90%e100% of cases and can involve virtually all areas ofthe body including the mouth, nose, genitalia, eyes and visceral
organs. Visceral involvement is common and seen in over 2/3rd of
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mucosa, diffuse tracheal and bronchial inﬂammation with mucosal
injury and sloughing, glomerulonephritis and hepatitis [1e4].
The pathogenesis of SJS-TEN induced constrictive bronchiolitis/
bronchiolitis obliterans (BO) is not completely clear, but likely re-
ﬂects severe bronchial epithelial injury and subsequent scarring in
a process akin to that seen in other mucous membranes. Damage to
the bronchiolar epithelium due to immune complex deposition in
SJS-TEN may initiate necrosis and subsequent exudation of ﬁbrin
and inﬂammatory cells into the airways [5]. Obliteration of bron-
chiolar lumens can then develop due to formation of ﬁbrous
granulation tissue. BO is a clinical diagnosis and pathologic
conﬁrmation is not mandatory for diagnosis. Lung involvement in
SJS-TEN appears to be quite common with both early and delayed
presentations. Onset of BO has been reported to occur from 5 days
to 10 months after the development of SJS [5e8]. In a prospective
study of 41 SJS-TEN patients by Lebargy and colleagues, bronchial
epithelial involvement was noted in 27% of cases [5]. Bronchoscopy
ﬁndings were consistent with epithelial sloughing in the proximal
airways. In the autopsied lungs of patients with BO after SJS-TEN,
Sugino and colleagues noted extensive occlusion of bronchi at the
4th and 5th generation bronchi and beyond [7]. These occlusive
lesions were sporadically and intermittently located from the small
bronchi all the way to the membranous bronchioles. Common
pulmonary manifestations included dyspnea, bronchial hyperse-
cretion, hypoxemia, atelectasis, pulmonary edema, need for me-
chanical ventilation and superimposed bacterial pneumonias.
The risk for SJS-TEN appears to be the highest in the ﬁrst few
weeks (8 weeks) after initiation of the culprit medication as was
the case in our patient. Treatment of SJS-TEN should begin with the
prompt withdrawal of the culprit drug. A multidisciplinary
approach is necessary to manage the diffuse skin, ocular, mucous
membrane and visceral organ involvement. Respiratory involve-
ment is treated with airway humidiﬁcation, bronchodilators and
chest physiotherapy. Around 25% of TEN cases may require me-
chanical ventilationwith poor outcomes and highmortality rates in
patients with severe respiratory tract involvement. Severe cases of
SJS-TEN are best treated in burn centers with studies showing that
prompt referral to a burn center is associated with improved sur-
vival [2]. No randomized controlled studies exist for intravenous
immunoglobulins, systemic corticosteroids, cyclosporine,cyclophosphamide, plasmapheresis, hemodialysis and other ther-
apies that are sporadically used in SJS-TEN.
3. Conclusion
In conclusion, we present a rare case of severe bronchiolitis
obliterans following phenytoin induced SJS-TENS. This case serves
to highlight the severe and long term respiratory impairment that
can occur in the setting of SJS-TEN induced bronchiolitis obliterans.
Unfortunately, effective therapies for the treatment of SJS-TEN do
not exist and supportive therapies with prompt discontinuation of
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